AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
indigo carmine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4575 | 860-22-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Indolesulfonic acid used as a dye in renal function testing for the detection of nitrates and chlorates, and in the testing of milk. It is a dye excreted by the kidney through tubular secretion and enhances visualization of the ureteral orifices by its deep blue color.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | AAK1,ACVR1B,ACVR2A,ACVR2B,ACVRL1,AKT1,AKT2,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BLK,BMX,BRAF,BTK,CAMK2A,CAMK2B,CAMK2D,CAMK2G,CDK1,CDK14,CDK16,CDK19,CDK2,CDK3,CDK4,CDK5,CDK9,CHEK1,CHUK,CLK4,CSF1R,DDR1,DYRK1B,DYRK2,DYRK3,EGFR,EIF2AK3,EPHA2,EPHB4,ERBB2,ERBB4,FGFR1,FGFR4,FLT1,FLT3,FLT4,FYN,GRK2,GRK3,GSK3A,GSK3B,HASPIN,HIPK2,IGF1R,IKBKB,INSR,IRAK1,ITK,JAK1,JAK2,JAK3,KDR,KIT,LCK,LYN,MAP2K1,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K14,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP3K8,MAP3K9,MAP4K1,MAP4K2,MAP4K3,MAP4K5,MAPK1,MAPK10,MAPK12,MAPK14,MAPK7,MAPK8,MAPK9,MAPKAPK2,MAPKAPK5,MARK1,MARK2,MARK4,MELK,MET,MINK1,MTOR,NTRK1,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM1,PIM2,PIM3,PLK1,PRKAA1,PRKAA2,PRKCD,PRKCZ,PRKDC,PTK2,SGK1,SIK2,SIK3,SRC,STK10,STK17A,STK33,SYK,TBK1,TEK,TGFBR1,TNIK,TTK,UHMK1,ULK1,ULK2,ZAP70 | 138 | |||
| kinase-selectivity-class | AAK1,ACVR2A,ACVR2B,ALK,AURKA,AURKB,AURKC,AXL,BRAF,CAMK2A,CAMK2B,CAMK2D,CDK1,CDK16,CDK2,CDK3,CDK4,CDK6,CDK7,CDK9,CLK2,CLK4,DDR1,DYRK1B,DYRK2,DYRK3,EIF2AK3,EPHA2,EPHB4,ERBB2,FLT3,FLT4,GRK2,GSK3A,GSK3B,HASPIN,HIPK2,IKBKB,IRAK1,IRAK3,JAK1,JAK2,KDR,KIT,LRRK2,MAP2K3,MAP2K6,MAP3K11,MAP3K14,MAP3K2,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAP4K5,MAPK1,MAPK12,MAPK7,MAPK8,MARK4,MET,MINK1,MST1R,MTOR,NTRK3,PDK1,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM3,PRKDC,SIK2,SIK3,SRC,STK10,STK16,STK33,SYK,TEK,TGFBR1,TNIK,TTK,TYRO3,ULK1,ULK2,ZAP70 | 88 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 8, 2022 | FDA | PROVEPHARM SAS |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anaphylactic shock | 19.73 | 18.99 | 3 | 3 | 31614 | 90596827 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | V04CH02 | VARIOUS DIAGNOSTIC AGENTS OTHER DIAGNOSTIC AGENTS Tests for renal function and ureteral injuries |
| MeSH PA | D004396 | Coloring Agents |
| CHEBI has role | CHEBI:50412 | two-colour indicator |
| CHEBI has role | CHEBI:77178 | histological dye |
| CHEBI has role | CHEBI:77182 | food colouring |
Related Drugs by ATC class:
V04CH Tests for renal function and ureteral injuries 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Visualization of the ureteral orifices | indication | 236168003 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 40MG/5ML (8MG/ML) | BLUDIGO | PROVEPHARM SAS | N216264 | July 8, 2022 | RX | SOLUTION | INTRAVENOUS | July 8, 2027 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4022196 | VUID |
| N0000148133 | NUI |
| 4018104 | VANDF |
| 4020216 | VANDF |
| 4022196 | VANDF |
| 4041712 | VANDF |
| CHEBI:31695 | CHEBI |
| CHEMBL2105023 | ChEMBL_ID |
| DB11577 | DRUGBANK_ID |
| 227312 | RXNORM |
| 4874 | MMSL |
| 6084 | MMSL |
| NOCODE | MMSL |
| d03700 | MMSL |
| 001233 | NDDF |
| 002341 | NDDF |
| 010433 | NDDF |
| 412548006 | SNOMEDCT_US |
| 783880009 | SNOMEDCT_US |
| C0021219 | UMLSCUI |
| D007203 | MESH_DESCRIPTOR_UI |
| 2723854 | PUBCHEM_CID |
| D01563 | KEGG_DRUG |
| D3741U8K7L | UNII |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Bludigo | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-840 | INJECTION | 8 mg | INTRAVENOUS | NDA | 27 sections |
| Indigo Carmine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4520 | INJECTION, SOLUTION | 8 mg | INTRAMUSCULAR | UNAPPROVED DRUG OTHER | 13 sections |
| BLUDIGO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 81284-315 | INJECTION | 8 mg | INTRAVENOUS | NDA | 25 sections |
| BLUDIGO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 81284-315 | INJECTION | 8 mg | INTRAVENOUS | NDA | 25 sections |